Sotagliflozin Cuts MACE Risk By 23% in Patients with Type 2 Diabetes, CKD
The Breakthrough Impact of Sotagliflozin in Cardiovascular Health Sotagliflozin, an innovative dual inhibitor of sodium-glucose cotransporter (SGLT) 1 and 2, is making waves in the medical field with its dual benefits for patients battling type 2 diabetes (T2D) and chronic kidney disease (CKD). Recent analyses, such as the SCORED trial, showcase the compound’s potential to … Read more